These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 1552655)
1. The effect of pretreatment with moricizine on early arrhythmia resulting from myocardial ischemia in rats. He ZS; Komori S; Tamura K; Hashimoto K Jpn Circ J; 1992 Mar; 56(3):286-91. PubMed ID: 1552655 [TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of moricizine on reperfusion induced tachyarrhythmias in rats--a comparison study with disopyramide and mexiletine. He ZS; Komori S; Tamura K; Hashimoto K Jpn Circ J; 1992 Aug; 56(8):861-5. PubMed ID: 1527898 [TBL] [Abstract][Full Text] [Related]
3. Effects of bidisomide (SC-40230), a new class I antiarrhythmic agent, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats; comparison with mexiletine and disopyramide. Komori S; Sano S; Li BH; Matsumura K; Naitoh A; Mochizuki S; Ishihara T; Watanabe A; Umetani K; Ijiri H Heart Vessels; 1995; 10(1):7-11. PubMed ID: 7537263 [TBL] [Abstract][Full Text] [Related]
4. Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine. Komori S; Sawanobori T; Tamura K; Kane KA; Parratt JR Jpn J Pharmacol; 1994 Jul; 65(3):193-200. PubMed ID: 7799519 [TBL] [Abstract][Full Text] [Related]
5. [Comparison of the efficacy of moricizine and disopyramide in the treatment of ventricular extrasystoles]. Fauchier JP; Babuty D; Rouesnel P; Cosnay P; Estepo J Arch Mal Coeur Vaiss; 1991 Apr; 84(4):553-60. PubMed ID: 1712193 [TBL] [Abstract][Full Text] [Related]
6. Moricizine: a new class I antiarrhythmic. Mann HJ Clin Pharm; 1990 Nov; 9(11):842-52. PubMed ID: 2272151 [TBL] [Abstract][Full Text] [Related]
7. Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias. Fitton A; Buckley MT Drugs; 1990 Jul; 40(1):138-67. PubMed ID: 2202581 [TBL] [Abstract][Full Text] [Related]
8. Antifibrillatory properties of alinidine after coronary artery occlusion in rats. Harron DW; Brezina M; Lillie C; Kobinger W Eur J Pharmacol; 1985 Apr; 110(3):301-8. PubMed ID: 4007054 [TBL] [Abstract][Full Text] [Related]
9. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine. Snyder DW J La State Med Soc; 1989 May; 141(5):21-5. PubMed ID: 2499645 [TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic efficacy of Ethmozine (moricizine HCl) compared with disopyramide and propranolol. Pratt CM; Butman SM; Young JB; Knoll M; English LD Am J Cardiol; 1987 Oct; 60(11):52F-58F. PubMed ID: 3310586 [TBL] [Abstract][Full Text] [Related]
11. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195 [TBL] [Abstract][Full Text] [Related]
12. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829 [TBL] [Abstract][Full Text] [Related]
13. Effect of mexiletine on reperfusion-induced ventricular arrhythmias: comparison with lidocaine. Bonaduce D; Ferrara N; Abete P; Longobardi G; Leosco D; Canonico V; Morgano G; Rengo F Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):19-29. PubMed ID: 3827408 [TBL] [Abstract][Full Text] [Related]
14. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108 [TBL] [Abstract][Full Text] [Related]
15. Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias. Anderson JL Am J Cardiol; 1990 Feb; 65(8):32D-40D. PubMed ID: 2106254 [TBL] [Abstract][Full Text] [Related]
16. Moricizine: pharmacodynamic, pharmacokinetic, and therapeutic profile of a new antiarrhythmic. Vanerio G; Maloney JD Cleve Clin J Med; 1992; 59(1):79-86. PubMed ID: 1551218 [TBL] [Abstract][Full Text] [Related]
17. Ethmozine (moricizine HCl) therapy for complex ventricular arrhythmias. Hession MJ; Lampert S; Podrid PJ; Lown B Am J Cardiol; 1987 Oct; 60(11):59F-66F. PubMed ID: 3310587 [TBL] [Abstract][Full Text] [Related]
18. Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Hulting J; Rosenhamer G Acta Med Scand; 1976; 199(1-2):41-51. PubMed ID: 1251772 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, hemodynamic effects, and pharmacokinetics of high-dose moricizine during short- and long-term therapy. Salerno DM; Sharkey PJ; Granrud GA; Asinger RW; Hodges M Clin Pharmacol Ther; 1987 Aug; 42(2):201-9. PubMed ID: 3301153 [TBL] [Abstract][Full Text] [Related]
20. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. Cardiac Arrhythmia Suppression Trial II Investigators N Engl J Med; 1992 Jul; 327(4):227-33. PubMed ID: 1377359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]